105 related articles for article (PubMed ID: 589556)
21. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
22. A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.
Van Echo DA; Chiuten DF; Markus S; Wiernik PH
Cancer Clin Trials; 1981; 4(2):129-33. PubMed ID: 6166406
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
24. Clinical toxicity associated with tiazofurin.
Grem JL; Rubinstein L; King SA; Cheson BD; Hawkins MJ; Shoemaker DD
Invest New Drugs; 1990 May; 8(2):227-38. PubMed ID: 2200759
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of taxol using a 5-day intermittent schedule.
Legha SS; Tenney DM; Krakoff IR
J Clin Oncol; 1986 May; 4(5):762-6. PubMed ID: 2871137
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of pyrazofurin in advanced head and neck cancer.
Cheng E; Currie V; Wittes RE
Cancer Treat Rep; 1979; 63(11-12):2047-8. PubMed ID: 526937
[No Abstract] [Full Text] [Related]
27. A phase of I trial of 4'-epi-Adriamycin.
Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW
Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Maroun JA; Stewart DJ
Invest New Drugs; 1990; 8 Suppl 1():S33-9. PubMed ID: 2380015
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
30. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
32. [A phase II study of SM-5887 for advanced gastric cancer].
Tsushima K; Sakata Y; Munakata A; Sato T; Chiba Y; Nara H; Kawazu S; Matsukawa M; Ohmi T; Aizawa T
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1151-4. PubMed ID: 1647150
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
Lake-Lewin D; Myers J; Lee BJ; Young CW
Cancer Treat Rep; 1979 Aug; 63(8):1403-4. PubMed ID: 476714
[No Abstract] [Full Text] [Related]
34. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
38. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
40. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
Tabata M; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Fukutani H; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2361-6. PubMed ID: 2546503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
